RAMIPRIL
Duchenne Muscular Dystrophy
Catholic University, ItalySmall moleculePhase 4 / ApprovedDormant
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 46/ 100
- Competitive Position
- 81/ 100
Competitive context
56 Active assets in the Duchenne Muscular Dystrophy cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Viltolarsen NS Pharma, Inc. | Phase 4 | BBB |
Golodirsen Rare Disease Research, LLC | Phase 4 | BB |
Delandistrogene Moxeparvovec Sarepta Therapeutics, Inc. | Phase 3 | BB |
Aoc 1044 Avidity Biosciences, Inc. | Phase 3 | BB |
Glutamine Assistance Publique - Hôpitaux de Paris | Phase 3 | BB |
View all 50 →
Same molecule, other indications
RAMIPRIL is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →